Oragenics Files Annual Report on Form 10-K for Fiscal Year 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Oragenics announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing a shareholder update on key operational and clinical milestones achieved during 2025 and progress made in the first quarter of 2026. The company said, "2026 STRATEGIC PRIORITIES: Enroll and dose patients in the Phase IIa clinical trial of ONP-002 in Australia; File an IND with the FDA to enable a U.S.-based clinical trials; Advance CNS portfolio expansion strategy by evaluating and pursuing synergistic asset acquisition opportunities." "2025 was the year we reset this company - financially, operationally, and strategically," reported Janet Huffman, the Company's Chief Executive Officer. "We raised capital, restored compliance, resolved a material legacy liability, and built the partnerships and infrastructure to compete at a higher level. None of that was easy, and none of it was accidental. It was the result of disciplined execution by a team that believes deeply in what ONP-002 can do for the 69 million people worldwide who suffer concussions every year with no approved pharmacological treatment available to them. 2026 is not about resetting. It is about executing. We are in the clinic. Patients will be dosed. And we are actively exploring the expansion of our CNS platform."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGEN
About OGEN
Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oragenics Activates Third Site for ONP-002 mTBI Trial in Australia
- Clinical Trial Advancement: Oragenics has received approval for the Royal Adelaide Hospital to act as the third site for the ONP-002 trial, marking significant progress in clinical research for mild traumatic brain injury (mTBI), with potential to be the first FDA-approved therapy for mTBI if successful.
- Site Expansion: The addition of this new site expands the trial to three locations, including Mackay Base Hospital and Alfred Health, enhancing the diversity and reliability of data collection, thereby improving the overall effectiveness of the clinical trial.
- FDA Meeting Request: Oragenics submitted a Type B meeting request to the FDA on June 26, 2026, aimed at gaining guidance on the future clinical development of ONP-002, demonstrating the company's commitment to strategic planning in drug development.
- Data Release Expectations: Data readouts from the ONP-002 clinical trial are anticipated in the fourth quarter of 2026, with plans for an investigational new drug (IND) submission, which, if positive, will lay the groundwork for future market introduction.
See More
Oragenics Advances ONP-002 Clinical Trial Progress
- Full Activation of Australian Trials: With the Royal Adelaide Hospital's approval on June 29, 2026, all three Phase IIa trial sites in Australia are now active and enrolling participants, marking a significant milestone in Oragenics' clinical strategy for mTBI treatment.
- First Participant Enrolled: Alfred Health enrolled its first participant on June 21, 2026, joining Mackay Base Hospital, indicating positive progress in participant recruitment that will support subsequent data analysis.
- FDA Meeting Request Submitted: On June 26, 2026, the company submitted a Type B meeting request to the FDA to gain guidance on the U.S. clinical development plan for ONP-002, laying the groundwork for its Investigational New Drug (IND) application targeted for Q4 2026.
- Safety Profile Confirmed: To date, no serious adverse events have been reported among all subjects dosed, demonstrating ONP-002's favorable safety profile, which will enhance confidence among investors and regulators as the company advances to the next clinical phases.
See More
Oragenics Q1 Financial Report Highlights
- Cash Balance: Oragenics reported a cash balance of $6.1 million for Q1, indicating stability in financial management despite market challenges.
- R&D Expense Increase: Research and development expenses reached $0.6 million, an 89% increase from the same period in 2025, reflecting the company's ongoing commitment to innovation and product development aimed at enhancing future competitiveness.
- Financial Transparency: The financial information released by the company provides a clear view of its operational status, aiding investors in assessing its long-term growth potential.
- Historical Performance Review: Historical earnings data for Oragenics offers crucial context for analyzing its financial health, helping investors understand the shifts in its market performance.
See More
Oragenics Signs LOI with Sigyn for Exclusive License
- Exclusive License Agreement: Oragenics has signed a Letter of Intent with Sigyn to obtain an exclusive license for CardioDialysis™ aimed at treating Traumatic Brain Injury (TBI) and other neurodegenerative diseases, marking a strategic move in the TBI treatment landscape.
- Innovative Treatment Strategy: Oragenics' ONP-002 is currently in Phase IIa clinical trials designed to directly target neuroinflammation by crossing the blood-brain barrier, while CardioDialysis™ complements this by purifying the bloodstream of inflammatory molecules, creating a dual-modality treatment approach.
- Significant Market Potential: With approximately 69 million individuals suffering brain injuries annually and no FDA-approved pharmacological treatments available, Oragenics' multi-faceted approach could significantly enhance recovery outcomes and address unmet medical needs in this space.
- Financial Terms Overview: Oragenics plans to issue 3.25 million shares of a new class of restricted preferred stock to Sigyn and expects to pay a 3% royalty on sales revenue post-FDA approval for six years, reflecting confidence in future market opportunities.
See More
Oragenics Reports Progress in ONP-002 Clinical Trial for mTBI
- Clinical Trial Progress: Oragenics has reported that two patients have been enrolled and eight doses of ONP-002 have been administered in its Phase IIa clinical trial for mild traumatic brain injury, marking a significant advancement in the program.
- Trial Design and Enrollment: The study is designed to enroll 40 patients at Mackay Base Hospital in Queensland, Australia, with participants receiving their first dose within 12 hours of concussion and continuing treatment for up to 30 days.
- Market Need and Potential: With an estimated 69 million cases of traumatic brain injury globally each year and no FDA-approved pharmacological treatments available, ONP-002 could become the first pharmacological standard of care in a market projected to exceed $9 billion by 2030 if successful.
- Company Outlook and Strategy: Oragenics' CEO noted that the early enrollment momentum reflects strong site readiness and the significant unmet need in concussion care, with plans for U.S. Phase IIb studies pending FDA approval of an Investigational New Drug application.
See More
Oragenics Initiates Phase 2a Trial for ONP-002 in Concussion Treatment
- Trial Launch: Oragenics Inc. announced the dosing of the first patient in the Phase 2a trial for ONP-002, its candidate for treating concussions and mild traumatic brain injury, marking a significant step in a field lacking approved pharmacological treatments.
- Drug Characteristics: ONP-002 is a first-in-class intranasal neurosteroid designed to reduce neuroinflammation, oxidative stress, and edema in the brain, developed using Oragenics' proprietary dry powder spray technology, with promising results from earlier studies enhancing its market potential.
- Trial Design: The Phase 2a trial is a randomized, placebo-controlled study that plans to administer ONP-002 to 40 patients within 12 hours of a concussion, with safety and tolerability evaluated through follow-up visits and neurocognitive testing.
- Future Plans: The company expects to file an investigational new drug (IND) application by the fourth quarter of 2026, after which Phase 2b will be initiated, indicating its long-term strategic focus on brain injury treatment.
See More
Oragenics Activates Third Site for ONP-002 mTBI Trial in Australia
- Clinical Trial Advancement: Oragenics has received approval for the Royal Adelaide Hospital to act as the third site for the ONP-002 trial, marking significant progress in clinical research for mild traumatic brain injury (mTBI), with potential to be the first FDA-approved therapy for mTBI if successful.
- Site Expansion: The addition of this new site expands the trial to three locations, including Mackay Base Hospital and Alfred Health, enhancing the diversity and reliability of data collection, thereby improving the overall effectiveness of the clinical trial.
- FDA Meeting Request: Oragenics submitted a Type B meeting request to the FDA on June 26, 2026, aimed at gaining guidance on the future clinical development of ONP-002, demonstrating the company's commitment to strategic planning in drug development.
- Data Release Expectations: Data readouts from the ONP-002 clinical trial are anticipated in the fourth quarter of 2026, with plans for an investigational new drug (IND) submission, which, if positive, will lay the groundwork for future market introduction.
See More
Oragenics Advances ONP-002 Clinical Trial Progress
- Full Activation of Australian Trials: With the Royal Adelaide Hospital's approval on June 29, 2026, all three Phase IIa trial sites in Australia are now active and enrolling participants, marking a significant milestone in Oragenics' clinical strategy for mTBI treatment.
- First Participant Enrolled: Alfred Health enrolled its first participant on June 21, 2026, joining Mackay Base Hospital, indicating positive progress in participant recruitment that will support subsequent data analysis.
- FDA Meeting Request Submitted: On June 26, 2026, the company submitted a Type B meeting request to the FDA to gain guidance on the U.S. clinical development plan for ONP-002, laying the groundwork for its Investigational New Drug (IND) application targeted for Q4 2026.
- Safety Profile Confirmed: To date, no serious adverse events have been reported among all subjects dosed, demonstrating ONP-002's favorable safety profile, which will enhance confidence among investors and regulators as the company advances to the next clinical phases.
See More
Oragenics Q1 Financial Report Highlights
- Cash Balance: Oragenics reported a cash balance of $6.1 million for Q1, indicating stability in financial management despite market challenges.
- R&D Expense Increase: Research and development expenses reached $0.6 million, an 89% increase from the same period in 2025, reflecting the company's ongoing commitment to innovation and product development aimed at enhancing future competitiveness.
- Financial Transparency: The financial information released by the company provides a clear view of its operational status, aiding investors in assessing its long-term growth potential.
- Historical Performance Review: Historical earnings data for Oragenics offers crucial context for analyzing its financial health, helping investors understand the shifts in its market performance.
See More
Oragenics Signs LOI with Sigyn for Exclusive License
- Exclusive License Agreement: Oragenics has signed a Letter of Intent with Sigyn to obtain an exclusive license for CardioDialysis™ aimed at treating Traumatic Brain Injury (TBI) and other neurodegenerative diseases, marking a strategic move in the TBI treatment landscape.
- Innovative Treatment Strategy: Oragenics' ONP-002 is currently in Phase IIa clinical trials designed to directly target neuroinflammation by crossing the blood-brain barrier, while CardioDialysis™ complements this by purifying the bloodstream of inflammatory molecules, creating a dual-modality treatment approach.
- Significant Market Potential: With approximately 69 million individuals suffering brain injuries annually and no FDA-approved pharmacological treatments available, Oragenics' multi-faceted approach could significantly enhance recovery outcomes and address unmet medical needs in this space.
- Financial Terms Overview: Oragenics plans to issue 3.25 million shares of a new class of restricted preferred stock to Sigyn and expects to pay a 3% royalty on sales revenue post-FDA approval for six years, reflecting confidence in future market opportunities.
See More
Oragenics Reports Progress in ONP-002 Clinical Trial for mTBI
- Clinical Trial Progress: Oragenics has reported that two patients have been enrolled and eight doses of ONP-002 have been administered in its Phase IIa clinical trial for mild traumatic brain injury, marking a significant advancement in the program.
- Trial Design and Enrollment: The study is designed to enroll 40 patients at Mackay Base Hospital in Queensland, Australia, with participants receiving their first dose within 12 hours of concussion and continuing treatment for up to 30 days.
- Market Need and Potential: With an estimated 69 million cases of traumatic brain injury globally each year and no FDA-approved pharmacological treatments available, ONP-002 could become the first pharmacological standard of care in a market projected to exceed $9 billion by 2030 if successful.
- Company Outlook and Strategy: Oragenics' CEO noted that the early enrollment momentum reflects strong site readiness and the significant unmet need in concussion care, with plans for U.S. Phase IIb studies pending FDA approval of an Investigational New Drug application.
See More
Oragenics Initiates Phase 2a Trial for ONP-002 in Concussion Treatment
- Trial Launch: Oragenics Inc. announced the dosing of the first patient in the Phase 2a trial for ONP-002, its candidate for treating concussions and mild traumatic brain injury, marking a significant step in a field lacking approved pharmacological treatments.
- Drug Characteristics: ONP-002 is a first-in-class intranasal neurosteroid designed to reduce neuroinflammation, oxidative stress, and edema in the brain, developed using Oragenics' proprietary dry powder spray technology, with promising results from earlier studies enhancing its market potential.
- Trial Design: The Phase 2a trial is a randomized, placebo-controlled study that plans to administer ONP-002 to 40 patients within 12 hours of a concussion, with safety and tolerability evaluated through follow-up visits and neurocognitive testing.
- Future Plans: The company expects to file an investigational new drug (IND) application by the fourth quarter of 2026, after which Phase 2b will be initiated, indicating its long-term strategic focus on brain injury treatment.
See More
